See more : Sintercom India Limited (SINTERCOM.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Opthea Limited (OPT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Opthea Limited, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Syscom Computer Engineering Co. (2453.TW) Income Statement Analysis – Financial Results
- VSO Electronics Co., Ltd. (6913.TWO) Income Statement Analysis – Financial Results
- Drägerwerk AG & Co. KGaA (DRW3.DE) Income Statement Analysis – Financial Results
- CoreCard Corporation (CCRD) Income Statement Analysis – Financial Results
- Kedge Construction Co., Ltd. (2546.TW) Income Statement Analysis – Financial Results
Opthea Limited (OPT)
About Opthea Limited
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 124.67K | 161.16K | 125.05K | 91.98K | 145.90K | 112.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.35K | 19.13K | 0.00 | 13.34K | 12.24K | 0.00 | 9.57K | 0.00 | 0.00 | 2.94B | 192.74K | 240.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 250.47K | 232.47K | 571.98K | 517.26K | 273.94K | 28.66K | 26.61K | 30.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 27.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 124.67K | -89.31K | -107.42K | -480.00K | -371.37K | -161.45K | -28.66K | -26.61K | -30.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.35K | 19.13K | 0.00 | 13.34K | 12.24K | 0.00 | 9.57K | 0.00 | -27.35K | 2.94B | 192.74K | 240.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | -55.42% | -85.91% | -521.85% | -254.54% | -143.51% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 176.33M | 181.56M | 108.46M | 34.71M | 17.48M | 31.35M | 24.89M | 4.84M | 3.58M | 4.28M | 3.40M | 3.14M | 3.68M | 7.02M | 3.65M | 3.62M | 3.27M | 2.67M | 1.20M | 533.75K | 349.78K | 106.50K | 144.69K | 553.00K | 186.15K | 358.33K | 600.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.67K | 0.00 | 0.00 |
| General & Administrative | 15.49M | 19.27M | 16.30M | 11.88M | 6.61M | 5.09M | 2.70M | 3.25M | 2.86M | 2.36M | 2.65M | 3.11M | 3.58M | 4.36M | 4.57M | 3.77M | 3.44M | 3.39M | 2.04M | 1.65M | 1.34M | 1.32M | 1.16M | 1.88M | 320.84K | 332.21K | 0.00 | 252.31K | 204.75K | 132.10K | 113.26K | 74.82K | 43.33K | 59.82K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 22.63M | 8.52M | 6.54M | 43.14K | 108.90K | 2.29M | 629.16K | 613.02K | 359.30K | 477.17K | 538.63K | 467.15K | 713.42K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 76.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.49M | 41.90M | 24.83M | 18.42M | 6.65M | 5.20M | 4.99M | 5.03M | 4.47M | 2.36M | 2.65M | 3.11M | 3.58M | 4.36M | 4.57M | 3.77M | 3.44M | 3.39M | 2.04M | 1.65M | 1.34M | 1.32M | 1.16M | 1.88M | 320.84K | 332.21K | 0.00 | 252.31K | 204.75K | 132.10K | 113.26K | 74.82K | 43.33K | 59.82K | 0.00 | 0.00 |
| Other Expenses | 152.46K | 12.30M | 0.00 | 0.00 | 0.00 | 56.76K | 2.03K | 1.23K | 6.23K | 48.00K | 183.04K | 29.55K | 199.06K | 78.32K | 2.12K | 106.79K | 5.76K | 130.52K | 50.38K | 22.90M | 5.33M | 11.79K | 96.84K | 875.00K | 1.59M | 2.79M | 73.54K | 81.79K | 11.03K | 47.58K | 432.57K | 9.00K | 10.00K | 20.00K | 10.00K | 4.53K |
| Operating Expenses | 191.97M | 223.46M | 133.29M | 53.13M | 24.71M | 36.27M | 29.88M | 9.87M | 8.05M | 6.80M | 6.59M | 6.88M | 8.90M | 12.27M | 8.68M | 8.46M | 8.26M | 14.38M | 3.55M | 2.32M | 1.80M | 2.94M | 1.32M | 12.76K | 520.09K | 14.89M | 13.11K | 6.78K | 208.69K | 135.65K | 114.72K | 74.82K | 44.07K | 68.25K | 7.93K | -7.55K |
| Cost & Expenses | 191.97M | 223.61M | 133.40M | 53.27M | 25.23M | 36.54M | 29.91M | 9.90M | 8.08M | 6.80M | 6.59M | 6.88M | 8.90M | 12.27M | 8.68M | 8.46M | 8.26M | 14.38M | 3.55M | 2.32M | 1.80M | 2.94M | 1.32M | 12.76K | 547.44K | 14.89M | 13.11K | 6.78K | 208.69K | 135.65K | 114.72K | 74.82K | 44.07K | 68.25K | 7.93K | -7.55K |
| Interest Income | 3.39M | 4.80M | 324.70K | 498.70K | 696.18K | 755.78K | 735.70K | 384.35K | 325.57K | 324.56K | 258.85K | 530.99K | 998.39K | 1.48M | 1.39M | 1.86M | 3.12M | 1.73M | 815.55K | 1.14M | 617.15K | 569.19K | 579.33K | 1.59M | 326.53K | 106.45K | 72.52K | 158.75K | 82.69K | 54.69K | 36.54K | 7.35K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 30.26M | 20.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 576.11K | 0.00 | 391.82K | 0.00 | 0.00 | 71.87K | 179.45K | 0.00 | 0.00 | 1.13K | 8.16K | 0.00 | 0.00 | 1.98M | 1.40M | 787.50 | 1.42K | 1.46K | 668.00 | 2.24K | 5.37K | 3.97K | 7.55K | |
| Depreciation & Amortization | 103.03K | 150.49K | 108.08K | 143.00K | 144.02K | 33.09K | 28.66K | 26.61K | 30.79K | 29.58K | 35.98K | 24.95K | 29.25K | 30.02K | 24.30K | 27.49K | 29.98K | 25.42K | 13.69K | 23.86K | 26.59K | 0.00 | 16.33K | 12.76K | 13.10K | 14.89M | 13.11K | 6.78K | 3.94K | 3.55K | 1.46K | -273.21K | 747.00 | 766.90 | 7.93K | -7.55K |
| EBITDA | -200.02M | -223.30M | -133.16M | -52.85M | -24.92M | -36.64M | -29.74M | -9.80M | -7.72M | -8.08M | -6.81M | -6.54M | -7.45M | -11.05M | -9.63M | -9.24M | -8.22M | -37.88M | -4.41M | 21.89M | -2.54M | -2.94M | -3.22M | -807.30K | -534.34K | 2.94B | 192.74K | 240.51K | -967.05K | -522.00K | -78.92K | -348.03K | -72.46K | -163.35K | -627.42K | -511.89K |
| EBITDA Ratio | -160,443.72% | -138,554.61% | -106,489.56% | -57,660.19% | -16,914.89% | -32,565.84% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -87,982.98% | -198,006.39% | 0.00% | 132,162.03% | -14,580.37% | 0.00% | -33,605.88% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -191.84M | -223.45M | -133.27M | -53.18M | -24.70M | -36.67M | -29.91M | -9.90M | -8.08M | -7.00M | -6.29M | -7.25M | -8.95M | -11.23M | -10.17M | -7.57M | -12.66M | -37.90M | -3.92M | 17.61M | -1.81M | -2.97M | -3.25M | -833.02K | -547.44K | -741.67K | -1.23M | -1.06M | -970.99K | -525.55K | -80.38K | -74.82K | -73.21K | -164.12K | -635.35K | -504.34K |
| Operating Income Ratio | -153,885.37% | -138,647.99% | -106,575.99% | -57,815.66% | -16,929.71% | -32,595.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -88,191.87% | -198,139.25% | 0.00% | 131,983.17% | -14,797.71% | 0.00% | -33,943.71% | 0.00% | 0.00% | -0.03% | -638.09% | -439.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -37.81M | -70.67M | -3.41M | -14.23M | 310.76K | 1.03M | 2.98M | 535.06K | -16.02K | 2.24M | 1.16M | 958.26K | 1.72M | 855.19K | 1.17M | -1.70M | 7.18M | 24.55M | -661.28K | -1.01M | 5.87M | 495.02K | -1.92M | -8.17K | 1.28M | 2.32M | -771.54K | -1.04M | 81.90K | 53.27K | 35.07K | -266.53K | 12.70K | 25.31K | 142.78K | 93.62K |
| Income Before Tax | -229.65M | -220.69M | -136.68M | -67.41M | -24.39M | -35.55M | -28.92M | -9.36M | -8.10M | -6.23M | -6.45M | -5.99M | -7.48M | -11.80M | -5.81M | -7.97M | -1.07M | 10.19M | -4.58M | 16.60M | 4.06M | -2.45M | -3.23M | -828.22K | 730.42K | 1.58M | -1.23M | -1.06M | -889.09K | -472.28K | -45.30K | -341.35K | -60.51K | -138.81K | -492.58K | -410.72K |
| Income Before Tax Ratio | -184,215.67% | -136,936.62% | -109,300.18% | -73,285.73% | -16,716.71% | -31,598.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7,445.89% | 53,289.60% | 0.00% | 124,394.23% | 33,158.07% | 0.00% | -33,788.24% | 0.00% | 0.00% | 0.05% | -638.09% | -439.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -9.41M | -8.81M | -8.69M | -6.62M | 8.27M | 14.64M | -12.02M | -3.17M | -1.57M | -2.09M | -2.69M | -1.42M | -2.46M | -831.43K | 93.06K | 37.02K | 1.12M | 4.85M | 252.37K | 2.79K | -5.87M | -83.76K | 85.58 | -39.80K | -1.28M | 2.37M | -1.98M | -1.40M | -1.13M | -665.00K | -62.00K | -511.00K | -81.00K | -181.00K | -621.00K | -544.00K |
| Net Income | -220.24M | -211.88M | -127.99M | -60.79M | -16.12M | -20.91M | -16.90M | -6.19M | -6.51M | -4.07M | -3.76M | -4.34M | -4.95M | -10.97M | -5.91M | -8.00M | -1.10M | 9.50M | -4.80M | 16.60M | 4.06M | -2.36M | -3.23M | -801.17K | 730.42K | 1.58B | -1.23M | -1.05M | -857.59K | -472.28K | -45.30K | -341.35K | -60.51K | -138.81K | -492.58K | -410.72K |
| Net Income Ratio | -176,665.73% | -131,469.80% | -102,353.69% | -66,087.58% | -11,047.04% | -18,587.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7,652.13% | 49,675.59% | 0.00% | 124,404.80% | 33,158.07% | 0.00% | -33,788.24% | 0.00% | 0.00% | 53.84% | -638.09% | -438.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.77 | -0.45 | -0.34 | -0.18 | -0.06 | -0.09 | -0.07 | -0.03 | -0.04 | -0.04 | -0.07 | -0.09 | -0.10 | -0.23 | -0.13 | -0.18 | -0.03 | 0.23 | -0.12 | 0.40 | 0.10 | -0.06 | -0.08 | -0.02 | 0.02 | 48.81 | -0.03 | -0.03 | -0.03 | -0.02 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -2.77 | -0.45 | -0.34 | -0.18 | -0.06 | -0.09 | -0.07 | -0.03 | -0.04 | -0.04 | -0.07 | -0.09 | -0.10 | -0.23 | -0.13 | -0.18 | -0.03 | 0.23 | -0.12 | 0.40 | 0.10 | -0.06 | -0.08 | -0.02 | 0.02 | 48.81 | -0.03 | -0.03 | -0.03 | -0.02 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 79.78M | 469.56M | 372.94M | 339.92M | 260.50M | 232.80M | 232.17M | 185.69M | 172.99M | 115.73M | 52.78M | 48.57M | 47.61M | 47.32M | 46.29M | 45.65M | 41.05M | 41.32M | 41.05M | 41.05M | 41.10M | 42.24M | 42.20M | 41.83M | 33.62M | 32.42M | 35.49M | 36.12M | 27.17M | 26.07M | 25.37M | 24.51M | 22.31M | 232.80M | 232.80M | 232.80M |
| Weighted Avg Shares Out (Dil) | 79.78M | 469.56M | 372.94M | 339.92M | 260.80M | 232.80M | 232.17M | 185.69M | 172.99M | 115.73M | 52.78M | 49.71M | 47.61M | 47.32M | 46.29M | 45.65M | 41.05M | 41.32M | 41.05M | 41.05M | 41.10M | 42.24M | 42.20M | 41.83M | 33.62M | 32.42M | 35.49M | 36.12M | 27.17M | 26.07M | 25.37M | 24.51M | 22.31M | 232.80M | 232.80M | 232.80M |
Opthea's Wet AMD Program to be Featured at FLORetina 2024
MELBOURNE, Australia, and Princeton, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today...
Opthea Appoints Kathy Connell to Board of Directors
Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT,...
Opthea Wet AMD Program to be Presented at Innovate Retina
MELBOURNE, Australia, and Princeton, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD),...
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024
MELBOURNE, Australia and PRINCETON, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD),...
Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept
Three consecutive commercial-scale batches successfully produced Major milestone for potential BLA filing of sozinibercept in wet AMD Progress update of drug product PPQ campaign expected in early 2025 MELBOURNE, Australia and PRINCETON, N.J., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Opthea...
Opthea to Have Significant Presence at the 24ᵗʰ EURETINA Congress and EURETINA Innovation Spotlight
MELBOURNE, Australia and PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD),...
Opthea Announces Executive Leadership Changes and Senior Hires
Daniel Geffken appointed Chief Financial Officer ad interim Mike Campbell appointed Chief Commercial Officer Three senior leaders appointed for Biometrics, Clinical Operations and Market Access MELBOURNE, Australia and PRINCETON, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT,...
Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference
MELBOURNE, Australia and PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD),...
Opthea Reports Full-Year Financial Results and Business Updates
Completed patient enrollment in COAST and ShORe pivotal wet AMD trials Financings extended cash runway through topline data readout of both trials in CY2025 Leadership appointments in preparation for regulatory filing and launch of sozinibercept MELBOURNE, Australia, and PRINCETON, N.J.,...
Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024
MELBOURNE, Australia and PRINCETON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD),...
Source: https://incomestatements.info
Category: Stock Reports